The article discusses research on reprogramming living cells that serve the therapeutic value of embryonic stem cells while sidestepping the public controversy that surrounds use of embryonic stem cells. Concepts underlying the article are highlighted with references made to induced pluripotent stem cells (IPSC), disease therapies that could derive from IPSCs, and how well IPSCs will perform compared to embryonic cells. The article also discusses the therapeutic promise and power of IPSCs, the use of cloning to produce IPSCs, and functional testing of IPSCs.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados